Literature DB >> 24002518

Recurrent hepatocellular carcinoma: it's the virus!

W Ray Kim1, Gregory J Gores.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24002518      PMCID： PMC4797623          DOI： 10.1200/JCO.2013.51.8381

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma.

Authors:  J S-W Wong; G L-H Wong; K K-F Tsoi; V W-S Wong; S Y-S Cheung; C-N Chong; J Wong; K-F Lee; P B-S Lai; H L-Y Chan
Journal:  Aliment Pharmacol Ther       Date:  2011-03-24       Impact factor: 8.171

2.  Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008.

Authors:  Ju Dong Yang; Bohyun Kim; Schuyler O Sanderson; Jennifer L St Sauver; Barbara P Yawn; Rachel A Pedersen; Joseph J Larson; Terry M Therneau; Lewis R Roberts; W Ray Kim
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

Review 3.  Hepatitis B virus X gene and hepatocarcinogenesis.

Authors:  Sue-Ann Ng; Caroline Lee
Journal:  J Gastroenterol       Date:  2011-06-08       Impact factor: 7.527

4.  Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study.

Authors:  Jianhua Yin; Nan Li; Yifang Han; Jie Xue; Yang Deng; Jie Shi; Weixing Guo; Hongwei Zhang; Hongyang Wang; Shuqun Cheng; Guangwen Cao
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

5.  Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.

Authors:  Chun-Ying Wu; Yi-Ju Chen; Hsiu J Ho; Yao-Chun Hsu; Ken N Kuo; Ming-Shiang Wu; Jaw-Town Lin
Journal:  JAMA       Date:  2012-11-14       Impact factor: 56.272

6.  Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B.

Authors:  A K Singal; H Salameh; Y-F Kuo; R J Fontana
Journal:  Aliment Pharmacol Ther       Date:  2013-05-28       Impact factor: 8.171

7.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 8.  Management of hepatitis B: our practice and how it relates to the guidelines.

Authors:  Suna Yapali; Nizar Talaat; Anna S Lok
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-06       Impact factor: 11.382
  8 in total
  5 in total

1.  Vascular invasion in hepatitis B virus-related hepatocellular carcinoma with underlying cirrhosis: possible associations with ascites and hepatitis B viral factors?

Authors:  Chuan Chen; Dong-Ping Chen; Yan-Yan Gu; Liang-Hao Hu; Dan Wang; Jin-Huan Lin; Zhao-Shen Li; Jing Xu; Ge Wang
Journal:  Tumour Biol       Date:  2015-04-02

2.  Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma.

Authors:  Xubiao Wei; Nan Li; Shanshan Li; Jie Shi; Weixing Guo; Yaxin Zheng; Shuqun Cheng
Journal:  BMC Cancer       Date:  2017-05-02       Impact factor: 4.430

3.  The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway.

Authors:  Jianxiang Chen; Muthukumar Rajasekaran; Hongping Xia; Xiaoqian Zhang; Shik Nie Kong; Karthik Sekar; Veerabrahma Pratap Seshachalam; Amudha Deivasigamani; Brian Kim Poh Goh; London Lucien Ooi; Wanjin Hong; Kam M Hui
Journal:  Gut       Date:  2016-03-03       Impact factor: 23.059

4.  Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.

Authors:  Hidenori Toyoda; Paul B S Lai; James O'Beirne; Charing C Chong; Sarah Berhane; Helen Reeves; Derek Manas; Richard P Fox; Winnie Yeo; Frankie Mo; Anthony W H Chan; Toshifumi Tada; Mercedes Iñarrairaegui; Arndt Vogel; Nora Schweitzer; Stephen L Chan; Bruno Sangro; Takashi Kumada; Philip J Johnson
Journal:  Br J Cancer       Date:  2016-03-29       Impact factor: 7.640

5.  Super-enhancer-driven AJUBA is activated by TCF4 and involved in epithelial-mesenchymal transition in the progression of Hepatocellular Carcinoma.

Authors:  Chi Zhang; Shi Wei; Wei-Peng Sun; Kai Teng; Miao-Miao Dai; Feng-Wei Wang; Jie-Wei Chen; Han Ling; Xiao-Dan Ma; Zi-Hao Feng; Jin-Ling Duan; Mu-Yan Cai; Dan Xie
Journal:  Theranostics       Date:  2020-07-11       Impact factor: 11.556
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.